From: Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance
 | Cytoplasmic (n = 19) (%) | Nucleocytoplasmic (n = 36) (%) | Test | P value |
---|---|---|---|---|
Gender | Â | Â | Fisher Exact Test | 0.39 |
 Male | 10 (52.63%) | 24 (66.7%) | ||
 Female | 9 (47.36%) | 12 (33.3%) | ||
Histological type clear | 10 (52.6%) | 19 (52.8%) | Chi square | 0.67 |
 Papillary | 2 (10.5%) | 5 (13.9%) | ||
 Chromophobe | 5 (26.3%) | 11 (30.6%) | ||
 Others | 2 (10.5%) | 1 (2.8%) | ||
Grade | ||||
 1 | 8 (42.1%) | 4 (11.1%) | Chi-square | 0.039* |
 2 | 7 (36.8%) | 14 (38.9%) | ||
 3 | 2 (10.5%) | 12 (33.3%) | ||
 4 | 2 (10.5%) | 6 (16.7%) | ||
Apoptosis | 3.05 ± 0.91 | 2.19 ± 0.71 | Mann–Whitney | 0.001** |
Mitosis | 2.4 ± 0.9 | 3.1 ± 1.2 | Mann–Whitney | 0.027* |
Tumour extent | ||||
 T1 | 11 (57.9%) | 6 (16.7%) | Chi-square | 0.011* |
 T2 | 6 (31.6%) | 15 (41.7%) | ||
 T3 | 2 (10.5%) | 13 (36.1%) | ||
 T4 | 0 (00%) | 2 (5.6%) | ||
LN | ||||
 Negative | 19 (100%) | 34 (94.4%) | Fisher Exact Test | 0.54 |
 Positive | 0 (00%) | 2 (5.6%) | ||
Stage | ||||
 I | 11 (57.9%) | 6 (16.7%) | Chi square | 0.009* |
 II | 6 (31.6%) | 14 (38.9%) | ||
 III | 2 (10.5%) | 14 (38.9%) | ||
 IV | 0 (00%) | 2 (5.6%) | ||
Response to chemotherapy | ||||
 No | 2 (10.5%) | 11 (30.6%) | Chi-square | 0.014* |
 Partial | 8 (42.1%) | 17 (47.2%) | ||
 complete | 5 (26.3%) | 1 (2.8%) |